Format

Send to

Choose Destination
Leukemia. 2008 Jun;22(6):1139-43. doi: 10.1038/leu.2008.77. Epub 2008 Apr 10.

Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas.

Author information

1
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA. feldman.andrew@mayo.edu

Abstract

Peripheral T-cell lymphomas (PTCLs) are fatal in the majority of patients and novel treatments, such as protein tyrosine kinase (PTK) inhibition, are needed. The recent finding of SYK/ITK translocations in rare PTCLs led us to examine the expression of Syk PTK in 141 PTCLs. Syk was positive by immunohistochemistry (IHC) in 133 PTCLs (94%), whereas normal T cells were negative. Western blot on frozen tissue (n=6) and flow cytometry on cell suspensions (n=4) correlated with IHC results in paraffin. Additionally, western blot demonstrated that Syk-positive PTCLs show tyrosine (525/526) phosphorylation, known to be required for Syk activation. Fluorescence in situ hybridization showed no SYK/ITK translocation in 86 cases. Overexpression of Syk, phosphorylation of its Y525/526 residues and the availability of orally available Syk inhibitors suggest that Syk merits further evaluation as a candidate target for pharmacologic PTK inhibition in patients with PTCL.

PMID:
18401419
PMCID:
PMC2778211
DOI:
10.1038/leu.2008.77
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center